We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biotech takes aim at large anti-estrogen markets.
- Authors
Hollmer, Mark
- Abstract
The article discusses the trends of increased focus towards anti-estrogen markets in the biotech industry. The article discusses about selective estrogen receptor modulator(SERM), developed jointly by Ligand Pharmaceuticals and Wyeth. The article highlights the rivalry between biotech firms and pharmaceutical companies for the development of SERM drugs. The article also mentions companies which are developing SERM drugs including Eli Lilly and QuatRx.
- Subjects
ESTROGEN antagonists; SELECTIVE estrogen receptor modulators; PHARMACEUTICAL industry; PHARMACEUTICAL biotechnology industry; LIGAND Pharmaceuticals Inc.; WYETH (Company : 1860-2009); ELI Lilly &; Co.; ECONOMIC competition; THERAPEUTICS
- Publication
Nature Biotechnology, 2006, Vol 24, Issue 12, p1455
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1206-1455